LBS Supports Duality Biotherapeutics’ Landmark HKEX IPO Celebration and ESG Tree Planting
LBS was honoured to play a key role in supporting the landmark Hong Kong IPO of Duality Biotherapeutics, a leading innovator in next-generation antibody-drug conjugates (ADCs), on April 15th.
Celebrating a Milestone: Listing Ceremony and IPO Dinner
We provided end-to-end event management for the Official Listing Ceremony at Hong Kong Exchanges and Clearing Limited (HKEX) and the prestigious IPO dinner. These events marked the culmination of Duality Biotherapeutics’ (DualityBio) journey to becoming a publicly listed company (Stock Code: 9606.HK), representing a major milestone as the largest Chapter 18A biotech IPO on HKEX in nearly four years. It was a true privilege to witness Dr. Zhu Zhongyuan, CEO of DualityBio, and Dr. Qiu Yang, CSO, ring the opening bell, a moment of shared pride and excitement. The dinner offered a meaningful opportunity for the management team, investors, including cornerstone investors such as BioNTech, LAV Star, Lake Bleu Prime, Lake Bleu Innovation, TruMed, along with other leading Chinese funds, partners and advisors to come together and celebrate this pivotal achievement.
Rooted in Responsibility: Participating in a Symbolic Tree-Planting Activity
Following its successful listing, DualityBio further demonstrated its commitment to sustainability and corporate responsibility by participating in a meaningful tree-planting activity. Organised by Rooftop Republic Urban Farming, an award-winning social enterprise committed to creating sustainable cities and communities powered by urban farming, the event took place atop the Bank of America Tower and Metroplaza, where the management team planted greenery as a symbolic gesture of growth and environmental stewardship. LBS was proud to participate in this inspiring initiative, which reflects DualityBio’s dedication to community impact and long-term sustainability.
Driving Success in Hong Kong’s Capital Markets
From high-profile ceremonial moments to the celebratory gathering and meaningful sustainability-focused planting initiatives, LBS ensured seamless execution that enabled DualityBio to effectively engage its stakeholders and amplify its successful market debut. Our comprehensive logistical and operational support allowed the DualityBio team to focus on this significant milestone and their vision of becoming a Global BioPharma.
Congratulations to Dr. Zhu Zhongyuan, Dr. Qiu Yang, and the entire DualityBio team on their successful listing. It was a privilege for LBS to support this important milestone, drawing on our event management experience to orchestrate high-impact engagements that energise Hong Kong’s capital markets and support our clients’ strategic goals.
Through our strategic event management capabilities, From enhancing visibility across financial and corporate audiences to highlighting DualityBio’s commitment to innovation and sustainability, we were proud to help bring their story to life. We look forward to continuing our partnership and supporting the next chapter of biotech growth in Hong Kong and beyond.
Photo | Official Listing ceremony (From left to right: Bonnie Chan, CEO of Hong Kong Exchanges and Clearing Limited (HKEX) with Dr. Zhu Zhongyuan, CEO of Duality Biotherapeutics and Dr. Qiu Yang, CSO of Duality Biotherapeutics)
Photo | Bell-ringing ceremony (From left to right: CSO Dr. Yang Qiu and CEO Dr. Zhu Zhongyuan)
About Duality Biotherapeutics
Duality Biologics Biotherapeutics (9606.HK) is a clinical-stage biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company has built multiple proprietary ADC technology platforms with global intellectual property rights. Driven by deep insights into disease biology, DualityBio has established a rich clinical pipeline and is conducting global multi-center clinical trials across more than 17 countries, enrolling over 2,000 patients. The company has also entered multiple global out-licensing collaborations with leading pharmaceutical and biotech companies. As a global innovation engine in ADCs, DualityBio continues to develop the next wave of ADC therapies, including bispecific ADCs, novel mechanism payload ADCs, and autoimmune ADCs. For more information, please visit: www.dualitybiologics.com
